Dexin Medical's DragonFly™ Transcatheter Mitral Valve Clip Gains Market Approval in Argentina and Vietnam, Accelerating Global Expansion

Nov 20, 2025 18:00 CST Updated 18:00

Valgen Medtech

Minimally Invasive Interventional Device Developer

Recently, Valgen Medtech's core product, the DragonFly™ Transcatheter Mitral Valve Clip System, successfully received marketing approval in Argentina and Vietnam. The product obtained approval from the Chinese National Medical Products Administration (NMPA) in November 2023, and is set to achieve EU MDR certification in April 2025. It has also progressively gained approvals from regulatory authorities in Turkey, Indonesia, Peru, Colombia, Hong Kong, and other countries/regions, marking a continued acceleration in Valgen Medtech's international expansion.

The breakthroughs in these two markets have laid a solid foundation for the subsequent global commercialization of DragonFly™.

The foundation for DragonFly™'s successful entry into the international market lies in its effective resolution of core clinical challenges.

In the face of the complexity of mitral valve anatomy,DragonFly™Through its visual and scaled quantitative operating system, it provides the operator with clear operational guidance and feedback.This not only shortens the learning curve, enabling more doctors to quickly master the technique, but also ensures surgical efficiency and success rates through standardized operational procedures.

Besides,Through the valve clipFree-angle locking combined with central occlusion net balances residual regurgitation and transvalvular pressure gradient, while considering immediate tension and long-term stability.

These technological advantages have ultimately translated into excellent clinical outcomes and gained international recognition. On November 16-18, at the world's top academic conference in the field of heart valvesPCR London Valves 2025Up,Global Valve Disease Experts,Director of the Cardiac Surgery Department and Director of the Valve Center at San Raffaele Scientific InstituteProfessor Francesco MaisanoSpecial Lecture on the Latest Clinical Results of DragonFly™ for Mitral Regurgitation Treatment Sparked Structural Heart DiseaseExtensive Attention in the International Field, providing solid data endorsement for the global applicability of the product.Click here to learn more

The superior performance of the product is its "language" for global acceptance.DragonFly™Has gained attention and recognition from top international experts in interventional cardiology.

Professor Marcelo Aguero

Cardiology Institute of Corrientes, Argentina

Professor Marcelo Aguero, when sharing the experience of the first application in Argentina, fully affirmedDragonFly™The clinical practicality, he pointed out: "In the face of the complexity of the surgery,DragonFly™"With its outstanding stability and precise control feedback, it provides strong support for the surgeon to successfully perform the operation, which is particularly valuable in difficult cases."

Academician Wang Jian'an

President of the Second Affiliated Hospital of Zhejiang University School of Medicine

“DragonFly™At the 36-month primary effective endpoint for mitral regurgitation treatment, 82.5% of DMR patients achieved the composite goal of 'no death, no mitral valve reintervention, and MR ≤ 2+', indicating that over 80% of patients did not require retreatment, with regurgitation controlled to moderate or less; furthermore, there were no severe device-related adverse events such as device embolization.'

Dr. Zhang Tingchao
General Manager of Valgen Medtech

"The successful overseas launch of DragonFly™ stems from two core factors: first, our deep technical沉淀 and industrialization experience in the transcatheter mitral valve repair field, which ensures the product's卓越价值; second, our consistent commitment to 'Provide safer and more effective solutions for heart disease patients"Valgen Medtech's mission is to bring tangible benefits to patients and society worldwide. This, combined with its solid foundation, forms the strong confidence with which Valgen Medtech strides onto the global stage."

———— Previous Review ————